<a href="https://laohu8.com/S/MDCX">Medicus Pharma Ltd.</a> Announces Expansion of SKNJCT-003 Clinical Trial and Plans Acquisition of UK-Based Antev Ltd
Medicus Pharma Ltd. has announced an expansion of its Phase 2 clinical study for SKNJCT-003, which began randomizing patients in August 2024 across nine clinical sites in the United States. Following a positively trending interim analysis in March 2025, showing over 60% clinical clearance, the investigational review board has increased the number of study participants to 90 subjects. The interim results are preliminary and may not necessarily reflect the final study outcomes. Additionally, the company is expanding its clinical trial sites into Europe. The lead asset, SkinJect Inc., focuses on a novel treatment for non-melanoma skin cancer using a patented dissolvable doxorubicin-containing microneedle array. Furthermore, Medicus Pharma Ltd. will present at the BTIG Virtual Biotech Conference 2025, where Dr. Raza Bokhari, Executive Chairman and CEO, will participate in a fireside chat on July 30, 2025. The chat will be livestreamed for registered investors, and a recording will be available for conference attendees.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 259382) on July 21, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.